Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.8%.
The iShares Biotechnology ETF (IBB) fell 1.5%.
In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note. The firm raised its price target on Lilly's stock to $1,500 from $1,250. Lilly shares were down 0.8%.